TCRX NASDAQ
TScan Therapeutics, Inc.
1W: -5.7%
1M: -15.9%
3M: -69.5%
YTD: -68.6%
1Y: -84.7%
3Y: -88.0%
5Y: -95.9%
$0.32
+0.00 (+0.94%)
Weekly Expected Move ±11.0%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
0 bullish
1 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (28)
TScan Therapeutics (NASDAQ:TCRX) Stock Jumps 1% – Here’s What Happened
What is HC Wainwright’s Estimate for TCRX FY2026 Earnings?
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss
TScan Therapeutics GAAP EPS of -$0.22 misses by $0.01, revenue of $1M misses by $1.5M
Earnings Scheduled For May 6, 2026
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting
12 Health Care Stocks Moving In Tuesday's After-Market Session
TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Average Rating of “Hold” by Analysts
TScan Therapeutics (NASDAQ:TCRX) Shares Up 3% – Here’s What Happened
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Recommendation of “Hold” from Brokerages
12 Health Care Stocks Moving In Friday's Pre-Market Session
HC Wainwright Issues Positive Outlook for TCRX Earnings
Brokers Offer Predictions for TCRX FY2030 Earnings
TScan Therapeutics GAAP EPS of -$0.18 beats by $0.06, revenue of $2.57M beats by $0.15M
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates
Earnings Breakdown: TScan Therapeutics Q4
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities